Imugene delighted as first cohort 3 patient dosed in CHECKvacc trial

Imugene CEO and managing director Leslie Chong tells Proactive’s Andrew Scott that the first patient has been dosed in cohort three of the Phase 1 clinical trial of oncolytic virotherapy candidate, CHECKvacc. The first-in-human, Phase 1, single-centre, dose-escalation study is recruiting patients with triple negative breast cancer.